[{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CMC Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"AdhexPharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"CMC Pharmaceuticals \/ AdhexPharma","highestDevelopmentStatusID":"15","companyTruncated":"CMC Pharmaceuticals \/ AdhexPharma"}]

Find Clinical Drug Pipeline Developments & Deals by CMC Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : Mezofy (aripiprazole) works as a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors, for treating schizophrenia.

                          Product Name : Mezofy

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 16, 2025

                          Lead Product(s) : Aripiprazole

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : AdhexPharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 12, 2022

                          Lead Product(s) : Atropine Sulfate,Scopolamine

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : IND Enabling

                          Sponsor : US Department of Defense

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          03

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product with the aim to aid the military in treating organophosphate poisoning in service members.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 04, 2022

                          Lead Product(s) : Atropine Sulfate

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Undisclosed

                          Sponsor : US Department of Defense

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank